Louis Nisbet has become chairman of BioCity Nottingham in the UK. He will oversee the expansion of BioCity’s services to cater for increasing demand from both UK and international tenants. The recent arrival of former AstraZeneca and Pfizer employees launching new ventures, as well as the rapid growth of several existing tenants, makes the BioCity bioscience cluster an attractive central UK business location.
Marlow-based Nisbet is a venture partner with Kurma BioFund, Paris. His early pharmaceutical career in drug discovery research with Roche, Glaxo and Smith Kline gives him a global insight into the issues surrounding the development and commercialisation of new healthcare products and businesses. He will devote time in Nottingham with fellow Board directors to addressing the needs of new life science companies, in particular their financing requirements.
Nisbet said: ‘We will be looking to work with our clients and the large pharmaceutical companies, as well as private investors, to find innovative solutions to facilitate partnerships and financing that will suit everyone.’
Dr Louis Nisbet leads BioCity forward
BioCity Nottingham appoints new chairman
You may also like
Manufacturing
Continuous innovation: redefining the future of pharmaceutical manufacturing
In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced